T2 Biosystems CS (TTOO)

$0.08 -0.06 (-41.49%)
Market Cap 4.09M
Revenue (ttm) 7.19M
Net Income (ttm) -50.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -696.52%
Debt to Equity Ratio 0.00
Volume 4,010,500
Avg Vol 1,494,488
Day's Range N/A - N/A
Shares Out 21.04M
Stochastic %K 5%
Beta 0.35
Analysts Hold
Price Target $5.00

Company Profile

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 761 4646
Address:
101 Hartwell Avenue, Lexington, United States
AbbyBradshaw1
AbbyBradshaw1 Oct. 28 at 10:11 AM
$TTOO Setting up nicely today. Remember: discipline over emotion, process over outcome. Let’s trade smart and finish green. Stay informed about market trends and opportunities! @AbbyBradshaw1
0 · Reply
vincent_2025
vincent_2025 Oct. 28 at 3:09 AM
$TTOO Would love to hear John Sperzel's view on T2MR technology - now that he is with a competitor. Or are they??
1 · Reply
Stockinvestor73
Stockinvestor73 Oct. 28 at 2:06 AM
$TTOO what the hell happened here? i used to be in it but got out before split
0 · Reply
notTintin
notTintin Oct. 27 at 6:16 PM
$TTOO I know it's just pocket money, but who sells/buys those 17,500 shares? Strange.
1 · Reply
GatorYoYo
GatorYoYo Oct. 27 at 2:57 PM
$TTOO April 7th, 2025 End of the 6 week term sheet period and also the date of the resignation of CEO and CFO, before a short contract deal stint. Is it possible that a suitor was selected since then.... but a deal closure was airmarked for Q4 when capital returned to the Bio and Life Science sector and the acquiring company would be at their financial fittest?🤷🏽
0 · Reply
vincent_2025
vincent_2025 Oct. 26 at 8:04 PM
$TTOO Targeting innovation: Diagnostic analytics and tests remain highly attractive areas for investment. Innovation, particularly in artificial intelligence (AI) and patient-centric technology, continues to drive deal activity.
0 · Reply
vincent_2025
vincent_2025 Oct. 26 at 6:52 PM
$TTOO Ai Response... your DD required.. T2 Magnetic Resonance (T2MR) is considered a patient-centric technology because it drastically reduces the time to diagnose life-threatening conditions like sepsis, leading to faster, more effective treatment and better patient outcomes. Instead of focusing on patient self-management, as some digital health tools do, T2MR is patient-centric by optimizing the clinical processes that directly impact patient health.
1 · Reply
vincent_2025
vincent_2025 Oct. 26 at 6:23 PM
$TTOO AI response your DD required... Geopolitical and regulatory uncertainties Strained international relations: Trade wars and geopolitical tensions, such as ongoing conflicts in Europe and the Middle East, have disrupted global supply chains and created higher operational uncertainties and costs. Tariffs, in particular, could increase the costs of devices, jeopardizing profitability for both manufacturers and hospitals. How the diagnostics sector is responding Despite the challenges, the medical diagnostics sector has seen continued M&A activity, though with different characteristics: Resilience and stabilization: Reports from late 2024 and mid-2025 show that the broader healthcare M&A market began to stabilize as economic uncertainties eased, with deal volume remaining steady or slightly increasing, particularly in life sciences and digital health.
1 · Reply
bjay11
bjay11 Oct. 26 at 3:27 PM
$TTOO
0 · Reply
tcamp923
tcamp923 Oct. 25 at 5:46 AM
$TTOO ye of little faith 😵‍💫
0 · Reply
Latest News on TTOO
No data available.
AbbyBradshaw1
AbbyBradshaw1 Oct. 28 at 10:11 AM
$TTOO Setting up nicely today. Remember: discipline over emotion, process over outcome. Let’s trade smart and finish green. Stay informed about market trends and opportunities! @AbbyBradshaw1
0 · Reply
vincent_2025
vincent_2025 Oct. 28 at 3:09 AM
$TTOO Would love to hear John Sperzel's view on T2MR technology - now that he is with a competitor. Or are they??
1 · Reply
Stockinvestor73
Stockinvestor73 Oct. 28 at 2:06 AM
$TTOO what the hell happened here? i used to be in it but got out before split
0 · Reply
notTintin
notTintin Oct. 27 at 6:16 PM
$TTOO I know it's just pocket money, but who sells/buys those 17,500 shares? Strange.
1 · Reply
GatorYoYo
GatorYoYo Oct. 27 at 2:57 PM
$TTOO April 7th, 2025 End of the 6 week term sheet period and also the date of the resignation of CEO and CFO, before a short contract deal stint. Is it possible that a suitor was selected since then.... but a deal closure was airmarked for Q4 when capital returned to the Bio and Life Science sector and the acquiring company would be at their financial fittest?🤷🏽
0 · Reply
vincent_2025
vincent_2025 Oct. 26 at 8:04 PM
$TTOO Targeting innovation: Diagnostic analytics and tests remain highly attractive areas for investment. Innovation, particularly in artificial intelligence (AI) and patient-centric technology, continues to drive deal activity.
0 · Reply
vincent_2025
vincent_2025 Oct. 26 at 6:52 PM
$TTOO Ai Response... your DD required.. T2 Magnetic Resonance (T2MR) is considered a patient-centric technology because it drastically reduces the time to diagnose life-threatening conditions like sepsis, leading to faster, more effective treatment and better patient outcomes. Instead of focusing on patient self-management, as some digital health tools do, T2MR is patient-centric by optimizing the clinical processes that directly impact patient health.
1 · Reply
vincent_2025
vincent_2025 Oct. 26 at 6:23 PM
$TTOO AI response your DD required... Geopolitical and regulatory uncertainties Strained international relations: Trade wars and geopolitical tensions, such as ongoing conflicts in Europe and the Middle East, have disrupted global supply chains and created higher operational uncertainties and costs. Tariffs, in particular, could increase the costs of devices, jeopardizing profitability for both manufacturers and hospitals. How the diagnostics sector is responding Despite the challenges, the medical diagnostics sector has seen continued M&A activity, though with different characteristics: Resilience and stabilization: Reports from late 2024 and mid-2025 show that the broader healthcare M&A market began to stabilize as economic uncertainties eased, with deal volume remaining steady or slightly increasing, particularly in life sciences and digital health.
1 · Reply
bjay11
bjay11 Oct. 26 at 3:27 PM
$TTOO
0 · Reply
tcamp923
tcamp923 Oct. 25 at 5:46 AM
$TTOO ye of little faith 😵‍💫
0 · Reply
tcamp923
tcamp923 Oct. 25 at 1:15 AM
$TTOO I spoke to Craig who confirmed CRG is still holding lMfao
3 · Reply
Cornishpasty
Cornishpasty Oct. 24 at 10:19 PM
$TTOO where to buy share ?
1 · Reply
jeni1988
jeni1988 Oct. 24 at 7:45 PM
$TTOO Whos trader order this????
0 · Reply
GatorYoYo
GatorYoYo Oct. 24 at 4:24 PM
$TTOO someone keeps on buying. 5000+ share purchase 🤷🏽‍♂️🙌🏽
1 · Reply
vincent_2025
vincent_2025 Oct. 24 at 3:32 PM
$TTOO "to create more sensitive, accurate, and comprehensive diagnostic and analytical tools" . .... wonder if this partnership is the door for T2MR ? https://www.businesswire.com/news/home/20251001395504/en/Thermo-Fisher-Scientific-Announces-RD-Partnership-with-AstraZeneca-BioVentureHub
0 · Reply
vincent_2025
vincent_2025 Oct. 24 at 3:23 PM
$TTOO AI Overview (your DD required) T2 magnetic resonance (T2MR) and fluorescence spectroscopy work together by combining their complementary strengths to create more sensitive, accurate, and comprehensive diagnostic and analytical tools. T2MR offers high penetration depth and detailed structural information, while fluorescence provides high sensitivity and specificity for detecting targeted molecules. How they work together A common method for combining these techniques is through the use of specially engineered multimodal nanoparticles that serve as both a fluorescent label and a T2 contrast agent.
0 · Reply
vincent_2025
vincent_2025 Oct. 24 at 3:20 PM
$TTOO Thermo Fisher Scientific uses fluorescence spectroscopy, both by manufacturing and selling fluorescence-based instruments and by using the technique in its own research and applications. The company offers a wide range of products for fluorescence analysis, including spectrometers, micro-volume systems, and online tools to help researchers with their experiments. Product lines: Thermo Fisher sells instruments that perform fluorescence spectroscopy, such as the Thermo Scientific Lumina fluorescence spectrometer and the NanoDrop family of micro-volume spectrophotometers. Broader spectroscopy portfolio: In addition to fluorescence, Thermo Fisher is a major manufacturer of other spectroscopic instruments, including X-ray fluorescence (XRF) spectrometers.
0 · Reply
__Chucky
__Chucky Oct. 24 at 2:23 PM
$TTOO The stock drop from $6–7 to $0.01–0.02 from massive dilution via debt-to-equity conversions and public offerings, not hidden CRG sales. CRG did sell 70M shares in 2023, but filed a Form 4S. Canon did received ~4.9M shares in 2016 via a stock deal; TTOO registered their resale on Form S-3 (March 2017) No public records show TTOO selling them on Canon's behalf without filings...... any resale would require Canon disclosures Public offerings cannot be used by CRG (or any major investor) to secretly dispose of owned shares without disclosure. Under SEC rules, public offerings require registration statements, even if they sell below 5%. They are subject to SEC Section 16 rules, requiring Form 4 filings for any sale of TTOO shares, regardless of size, due to their status as a major shareholder. They are also subject to stricter reporting under Rule 144, and any transaction in a public offering would require disclosure in the prospectus, naming them as a selling stockholder.
1 · Reply
vincent_2025
vincent_2025 Oct. 24 at 1:47 PM
$TTOO (AI response, (your DD required) Convergence of T2MR and fluorescence While T2MR and fluorescence are distinct, they can be combined into dual-modal systems for enhanced diagnostics and imaging. Hybrid nanoparticles: Nanoparticles can be synthesized to possess both magnetic and fluorescent properties. Structure: These typically consist of a magnetic core (for T2MR) and a fluorescent shell or a conjugated fluorescent molecule. Application: Such particles allow for both magnetic tracking (e.g., MRI) and fluorescent imaging (e.g., optical microscopy), offering a powerful research tool.
0 · Reply
StockDreamin
StockDreamin Oct. 24 at 11:51 AM
$TTOO where are the life saving machines?!
0 · Reply
charlieshim2015
charlieshim2015 Oct. 24 at 10:23 AM
$TTOO how mucj longer we have to anticipate the buyout news?
0 · Reply
vincent_2025
vincent_2025 Oct. 24 at 9:03 AM
$TTOO (TMO site) B·R·A·H·M·S PCT™ sensitive KRYPTOR™ takes the diagnosis to a level confirming sepsis. (TTOO site)T2MR diagnosis defines the Pathogen for targeted therapy. (AI response) Targeted antimicrobial therapy is a strategy that uses specific treatments to eliminate or control pathogens while minimizing harm to beneficial microbes, such as those in the gut microbiome. This approach aims to combat antimicrobial resistance and reduce side effects associated with broad-spectrum antibiotics by only targeting harmful bacteria.
1 · Reply